Table 2.
Frequency of non-serious adverse events
| Description of non-serious adverse events* | Total | Emtricitabine/Tenofovir | Colchicine+Rosuvastatin | Emtricitabine/ Tenofovir + Colchicine + Rosuvastatin | Standard of Care |
|---|---|---|---|---|---|
| Gastrointestinal (nausea, diarrhoea, epigastralgia) | 88 | 22 | 24 | 38 | 4 |
| Hepatic (elevation of transaminases, alkaline phosphatase, and bilirubin) | 67 | 15 | 17 | 24 | 11 |
| Non-specific (asthenia, cramps, diaphoresis) | 23 | 6 | 6 | 9 | 2 |
| Neurologic (headache, delirium, seizure episode) | 22 | 5 | 2 | 10 | 5 |
| Cardiovascular (hypertension, bradycardia, atrial fibrillation) | 21 | 6 | 4 | 6 | 5 |
| Renal (kidney injury, hematuria, and increased creatine phosphokinase) | 20 | 7 | 7 | 1 | 5 |
| Hematologic (Anemia, thrombocytopenia, thrombocytosis) | 16 | 2 | 5 | 5 | 4 |
| Allergic (Exanthema, rash, and allergic reaction) | 14 | 5 | 6 | 3 | 0 |
| Metabolic (diabetes, hyperglycemia and cholelithiasis) | 12 | 6 | 2 | 3 | 1 |
| Osteomuscular (contracture, weakness, myalgia) | 6 | 2 | 1 | 3 | 0 |
| Infectious (bacteremia, herpes zoster and catheter site infection) | 5 | 1 | 2 | 0 | 2 |
| Electrolytes (Hyperkalemia and hypokalemia) | 4 | 1 | 2 | 0 | 1 |
| Psychiatric (Anxiety, panic, and psychosis) | 3 | 1 | 0 | 1 | 1 |
| Respiratory (Dyspnea and pneumothorax) | 3 | 1 | 2 | 0 | 0 |
| Otolaryngological (Otorrhagia) | 2 | 1 | 1 | 0 | 0 |
| Dental (Tooth loss) | 1 | 0 | 1 | 0 | 0 |
⁎
We do not present information with relative frequencies (i.e., percentages) because some events occurred simultaneously in the same patients; therefore, it is difficult to have a denominator.